Announced
Financials
Tags
China
Friendly
Private
biotechnology company
Minority
Acquisition
Single Bidder
Pending
Biotechnology
Synopsis
NT Pharma, a pharmaceutical company in China, agreed to acquire a 40% stake in Kangchen, which focuses on the development of special drugs, for $51m. NT Pharma Group claims that the deal will bring about $4.8m in net profit. Proceeds will be used to pay the debt and embark on the partial redemption of the CPS, which is due on June 30, 2020.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.